Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

650
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
650

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Frontiers in immunology·2026
Same author

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.

Scientific reports·2026
Same author

Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.

Scientific reports·2026
Same author

Diagnostic Accuracy of Dual Energy CT for Bone Marrow Edema of the Sacroiliac Joints Compared with MRI: A Systematic Review.

Journal of clinical medicine·2026
Same author

Case Report: Niraparib-abiraterone in HRR-mutated metastatic castration-resistant prostate cancer: clinical insights from five cases.

Frontiers in oncology·2026

Related Experiment Video

Updated: Sep 2, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K

The latest developments in biomarkers predicting response to immunotherapy.

Giandomenico Roviello1, Melissa Bersanelli2, Martina Catalano3

  • 1Department of Health Sciences, Section of Clinical Pharmacology & Oncology, University of Florence, Viale Pieraccini, 6, Florence, 50139, Italy.

Immunotherapy
|August 4, 2022
PubMed
Summary

Identifying biomarkers for immune checkpoint inhibitors helps select patients for immunotherapy. This approach avoids disease progression in nonresponders and unnecessary toxicity.

Keywords:
biomarkersimmune checkpoints inhibitorsimmunotherapypredictive factorssolid tumors

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.5K

Related Experiment Videos

Last Updated: Sep 2, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.5K

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
  • Predicting patient response to ICIs remains a significant clinical challenge.
  • Accurate patient selection is crucial to maximize therapeutic benefits and minimize adverse effects.

Discussion:

  • Biomarkers are essential for predicting response to immune checkpoint inhibitors (ICIs).
  • Effective biomarkers can guide the selection of patients most likely to benefit from immunotherapy.
  • This strategy aims to prevent rapid disease progression in nonresponders and reduce treatment-related toxicity.

Key Insights:

  • Development of predictive biomarkers for ICI therapy is a critical area of research.
  • Biomarker-driven patient selection enhances immunotherapy efficacy.
  • Minimizing exposure to ineffective treatments improves patient outcomes and conserves resources.

Outlook:

  • Future research will focus on discovering and validating novel biomarkers for ICI response.
  • Integration of multi-omic data may yield more robust predictive models.
  • Personalized immunotherapy strategies based on biomarkers will become increasingly important in clinical practice.